Cargando…
Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
Vaccines and immunotherapeutic approaches to cancers with the advent of immune checkpoint inhibitors and chimeric antigen receptor-modified T cells have recently demonstrated preclinical success and entered clinical trials. Despite advances in these approaches and combinatorial therapeutic regimens,...
Autores principales: | Yin, Jie, Markert, James M., Leavenworth, Jianmei W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483455/ https://www.ncbi.nlm.nih.gov/pubmed/28695111 http://dx.doi.org/10.3389/fonc.2017.00136 |
Ejemplares similares
-
Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017) -
A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma
por: Takaoka, Hiroo, et al.
Publicado: (2011) -
Oncolytic virotherapy using herpes simplex virus: how far have we come?
por: Sokolowski, Nicolas AS, et al.
Publicado: (2015) -
Immune System, Friend or Foe of Oncolytic Virotherapy?
por: Filley, Anna C., et al.
Publicado: (2017) -
Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
por: Scanlan, Hayle, et al.
Publicado: (2022)